US Bancorp
VKTX icon

US Bancorp’s Viking Therapeutics VKTX Stock Holding History

US Bancorp’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
7,889
+266
+3% +$8.59K ﹤0.01% 1878
2026
Q1 		$248K Sell
7,623
-466
-6% -$15K ﹤0.01% 1899
2025
Q4 		$285K Sell
8,089
-2,364
-23% -$83.8K ﹤0.01% 1846
2025
Q3 		$275K Buy
10,453
+5,076
+94% +$151K ﹤0.01% 1836
2025
Q2 		$142K Buy
5,377
+584
+12% +$15.4K ﹤0.01% 2238
2025
Q1 		$116K Buy
4,793
+972
+25% +$30.7K ﹤0.01% 2326
2024
Q4 		$154K Buy
3,821
+9
+0.2% +$513 ﹤0.01% 2169
2024
Q3 		$241K Sell
3,812
-1,206
-24% -$70.8K ﹤0.01% 1937
2024
Q2 		$266K Sell
5,018
-1,924
-28% -$126K ﹤0.01% 1843
2024
Q1 		$569K Buy
6,942
+4,596
+196% +$205K ﹤0.01% 1423
2023
Q4 		$43.7K Buy
2,346
+937
+67% +$12.3K ﹤0.01% 2740
2023
Q3 		$15.6K Sell
1,409
-26,981
-95% -$386K ﹤0.01% 2990
2023
Q2 		$460K Sell
28,390
-5,879
-17% -$123K ﹤0.01% 1449
2023
Q1 		$571K Sell
34,269
-4,301
-11% -$44.4K ﹤0.01% 1337
2022
Q4 		$363K Buy
+38,570
New +$172K ﹤0.01% 1565
2021
Q4 		– Sell
-4,662
Closed -$29K – 4237
2021
Q3 		$29K Sell
4,662
-291
-6% -$1.8K ﹤0.01% 2940
2021
Q2 		$30K Sell
4,953
-49
-1% -$291 ﹤0.01% 2932
2021
Q1 		$32K Buy
5,002
+3,543
+243% +$24.9K ﹤0.01% 2809
2020
Q4 		$8K Sell
1,459
-2,466
-63% -$14.9K ﹤0.01% 3275
2020
Q3 		$23K Sell
3,925
-210
-5% -$1.45K ﹤0.01% 2765
2020
Q2 		$30K Sell
4,135
-108
-3% -$717 ﹤0.01% 2640
2020
Q1 		$20K Buy
4,243
+210
+5% +$1.29K ﹤0.01% 2756
2019
Q4 		$32K Buy
4,033
+46
+1% +$335 ﹤0.01% 2680
2019
Q3 		$27K Sell
3,987
-108
-3% -$802 ﹤0.01% 2727
2019
Q2 		$34K Sell
4,095
-56
-1% -$479 ﹤0.01% 2699
2019
Q1 		$41K Buy
+4,151
New +$34.7K ﹤0.01% 2582

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

US Bancorp's VKTX Position: Q2 2026 in Review

US Bancorp increased its Viking Therapeutics (VKTX) stake by 3.5% in Q2 2026, buying an estimated $8.59K and bringing the position to 7,889 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #1878.

US Bancorp first reported a position in VKTX in Q1 2019 and has held it in 26 quarters since. The position peaked at $571K in Q1 2023. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • US Bancorp held 7,889 shares of Viking Therapeutics worth $308K as of Q2 2026.
  • US Bancorp bought 266 Viking Therapeutics shares in Q2 2026, an estimated $8.59K.
  • Viking Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1878 holding.
  • US Bancorp first reported a position in Viking Therapeutics in Q1 2019 and has held it in 26 quarters since.
  • US Bancorp's Viking Therapeutics position peaked at $571K in Q1 2023.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.